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Formerly referred to as "regressive atypical 
histiocytosis". 
Clinics and pathology 
Phenotype/cell stem origin 
This entity is regarded ad a T-cell lymphoma. The 
neoplastic cells express the CD30 antigen, and show 
variable expression of T-cell markers. Clonal 
rearrangement of the T-cell receptor is usually found in 
approximately 60% of the cases. 
Epidemiology 
It accounts for approximately 9% of all cutaneous 
lymphomas. Median age at onset is 60 years. 
Pathology 
Usually the disease arises de novo in the skin and 
presents with a solitary reddish nodule, which may 
became ulcerated. Rarely, distinct nodules may be 
appreciated in a cutaneous area, or in multiple sites. 
The risk of disese dissemination at extracutaneous sites 
is very low in the presence of a solitary nodule. The 
neoplastic nodule is composed of large anaplastic cells 
with pleomorphic nucleus. Some multinucleated cells 
are also present, resembling Reed-Sternberg cells. 
Reactive neutrophils and macrophages infiltrate the 
lymphomatous lesion. Unlike systemic CD30+ 
anaplastic large cell lymphoma, the expression of the 
ALK protein is not found in primary cutaneous 
tumours. 
Treatment 
Approximately 25% of the cases may show 
spontaneous regression of the cutaneous nodule. 
Surgical excision with or without subsequent 
radiotherapy to the involved cutaneous site is curative 
in the majority of cases. Patients at risk of developing 
recurrence at extracutaneous sites (i.e. with multiple 
nodules at distant cutaneous sites) may require 
multiagent chemotherapy. 
Prognosis 
The prognosis is excellent in those patients with a 
solitary nodule undergoing complete surgical resection. 
Adequate systemic treatment usually attains durable 
complete responses in patients with disseminated 
disease, with a 90% overall survival at 5 years. 
Cytogenetics 
Note 
The tumour cells are difficult to grow in culture and 
few data are available. The t(2;5), usually associated 
with systemic anaplastic large cell lymphoma, is not 
found in this disease. Single cases with variant ALK 
translocations were described. In patients with 
extranodal anaplastic large cell lymphoma, recurrent 
breakpoints occurred at 1p36; 6p25 and 8q24; a 6q- 
chromosome was found in one patient. 
Cytogenetics molecular 
Comparative genomic hybridization studies disclosed 
chromosomal imbalances in approximately 40% of the 
cases. The most frequent gains involved chromosome 
1/1p and 5 (50% of the cases), 6,7,8/8p, and 19 (38%).  
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Gains involving chromosome 9 were also described. 
Other gains occurred less frequently at 3/3p, 7/7q, 10, 
12, 13, 15q and 20/20p. Recurrent losses were detected 
at 6q21 and 18p11. There is a positive correlation 
between the presence of chromosomal imbalances and 
clonal T-cell receptor gene rearrangement. Recurrent 
oncogene copy number gains involve FGFR1 at 8p11; 
NRAS at 1p13.2, RAF1 at 3p25, >CC: TXT: MYCN 
ID: 112> at 2p24.1, CTSB at 8p22, FES at 15q26.1 and 
CBAF2 at 21q22. The majority of cases investigated by 
real time PCR revealed amplification of the following 
genes: CTSB, RAF1, REL at 2p13; JUNB at 19p13. 
Gains involving chromosome 9 and losses involving 
chromosome 6q and 18p were seen in relapsing 
patients. 
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